Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Shares Outstanding (Weighted Average) (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Shares Outstanding (Weighted Average) data on record, last reported at $20.8 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 460.74% year-over-year to $20.8 million; the TTM value through Sep 2025 reached $20.8 million, up 460.74%, while the annual FY2024 figure was $3.4 million, 74.28% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $20.8 million in Q3 2025 per MBRX's latest filing, up from $15.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $28.6 million in Q3 2022 and bottomed at $1.9 million in Q4 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $13.5 million, with a median of $9.3 million recorded in 2025.
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 93.29% in 2023, then surged 519.89% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $26.9 million in 2021, then plummeted by 92.9% to $1.9 million in 2022, then grew by 3.6% to $2.0 million in 2023, then surged by 74.28% to $3.4 million in 2024, then skyrocketed by 504.92% to $20.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $20.8 million in Q3 2025, $15.5 million in Q2 2025, and $9.3 million in Q1 2025.